ESR1 and breast neoplasm: Analysis of The Cancer Genome Atlas's (TCGA) ER+ breast tumour cohort revealed alterations in the CDK4/CDK6/cyclin D pathway in about 35% of the patients, making them an ideal population for targeting CDK4 and CDK6 (Supplementary Fig. 1a).